Global Osteoarthritis Drugs Market Growth, Size, Trends Analysis - By Drug Type, By Route of Administration, By Anatomy, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Global Osteoarthritis Drugs Market Introduction and Overview

According to SPER market research, 'Global Osteoarthritis Drugs Market Size- By Drug Type, By Route of Administration, By Anatomy, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Osteoarthritis Drugs Market is predicted to reach 18.98 billion by 2034 with a CAGR of 7.13%.

Osteoarthritis therapeutics are medical treatments and interventions designed to control and alleviate the symptoms of osteoarthritis, a degenerative joint condition characterised by cartilage and bone breakdown. Analgesics, nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, and disease-modifying osteoarthritis medicines (DMOADs) are among the options. Physical therapy, lifestyle adjustments, and surgical treatments such as joint replacement are all available as treatment alternatives.

Restraints: Excessive consumption of osteoarthritis medicines, such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, can result in side effects such as cardiovascular risks, gastrointestinal problems, and kidney concerns. Long-term use of these pharmaceuticals may result in a variety of health problems, posing challenges for both users and manufacturers.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Connectivity, By Mounting

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Canadian Solar, CHINT Group, First Solar, JA SOLAR Technology Co., Ltd, JinkoSolar, LG Electronics, Shunfeng International Clean Energy Co., Ltd, The Solaria Corporation, Trina Solar.

Global Osteoarthritis Drugs Market Segmentation:

By Drug Type: Based on the Drug Type, Global Osteoarthritis Drugs Market is segmented as; Visco Supplementation Agents, NSAIDs, Analgesics, Corticosteroids.

By Route of Administration: Based on the Route of Administration, Global Osteoarthritis Drugs Market is segmented as; Oral, Parenteral, Topical.

By Anatomy: Based on the Anatomy, Global Osteoarthritis Drugs Market is segmented as; Ankle Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, Other Anatomies.

By Distribution Channel: Based on the Distribution Channel, Global Osteoarthritis Drugs Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacy.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25220

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTERs Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Global Osteoarthritis Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Osteoarthritis Drugs Market

7.Global Osteoarthritis Drugs Market, By Drug Type (USD Million) 2021-2034

7.1.Visco Supplementation Agents
7.2.Nonsteroidal Anti-Inflammatory Drugs
- 7.2.1.Naproxen
- 7.2.2.Aspirin
- 7.2.3.Diclofenac
- 7.2.4.Ibuprofen
- 7.2.5.Celecoxib
- 7.2.6.Meloxicam
- 7.2.7.Piroxicam
- 7.2.8.Ketoprofen
- 7.2.9.Other NSAIDs
7.3.Analgesics
- 7.3.1.Duloxetine
- 7.3.2.Acetaminophen
7.4.Corticosteroids
7.5.Other Drug Types

8.Global Osteoarthritis Drugs Market, By Route of Administration (USD Million) 2021-2034

8.1.Oral
8.2.Parenteral
8.3.Topical

9.Global Osteoarthritis Drugs Market, By Anatomy (USD Million) 2021-2034

9.1.Ankle Osteoarthritis
9.2.Hip Osteoarthritis
9.3.Knee Osteoarthritis
9.4.Shoulder Osteoarthritis
9.5.Other Anatomies

10.Global Osteoarthritis Drugs Market, By Distribution Channel (USD Million) 2021-2034

10.1.Hospital Pharmacies
10.2.Retail Pharmacies
10.3.Online Pharmacy

11.Global Osteoarthritis Drugs Market, (USD Million) 2021-2034

11.1.Global Osteoarthritis Drugs Market Size and Market Share

12.Global Osteoarthritis Drugs Market, By Region, (USD Million) 2021-2034

12.1.Asia-Pacific
- 12.1.1.Australia
- 12.1.2.China
- 12.1.3.India
- 12.1.4.Japan
- 12.1.5.South Korea
- 12.1.6.Rest of Asia-Pacific
12.2.Europe
- 12.2.1.France
- 12.2.2.Germany
- 12.2.3.Italy
- 12.2.4.Spain
- 12.2.5.United Kingdom
- 12.2.6.Rest of Europe
12.3.Middle East and Africa
- 12.3.1.Kingdom of Saudi Arabia
- 12.3.2.United Arab Emirates
- 12.3.3.Qatar
- 12.3.4.South Africa
- 12.3.5.Egypt
- 12.3.6.Morocco
- 12.3.7.Nigeria
- 12.3.8.Rest of Middle-East and Africa
12.4.North America
- 12.4.1.Canada
- 12.4.2.Mexico
- 12.4.3.United States
12.5.Latin America
- 12.5.1.Argentina
- 12.5.2.Brazil
- 12.5.3.Rest of Latin America

13.Company Profile

13.1.Anika Therapeutics
- 13.1.1.Company details
- 13.1.2.Financial outlook
- 13.1.3.Product summary
- 13.1.4.Recent developments
13.2.Assertio Holdings, Inc
- 13.2.1.Company details
- 13.2.2.Financial outlook
- 13.2.3.Product summary
- 13.2.4.Recent developments
13.3.Bayer AG
- 13.3.1.Company details
- 13.3.2.Financial outlook
- 13.3.3.Product summary
- 13.3.4.Recent developments
13.4.Bioventus
- 13.4.1.Company details
- 13.4.2.Financial outlook
- 13.4.3.Product summary
- 13.4.4.Recent developments
13.5.Ferring Pharmaceuticals Inc
- 13.5.1.Company details
- 13.5.2.Financial outlook
- 13.5.3.Product summary
- 13.5.4.Recent developments
13.6.GlaxoSmithKline plc
- 13.6.1.Company details
- 13.6.2.Financial outlook
- 13.6.3.Product summary
- 13.6.4.Recent developments
13.7.Novartis AG
- 13.7.1.Company details
- 13.7.2.Financial outlook
- 13.7.3.Product summary
- 13.7.4.Recent developments
13.8.Pacira Pharmaceuticals, Inc
- 13.8.1.Company details
- 13.8.2.Financial outlook
- 13.8.3.Product summary
- 13.8.4.Recent developments
13.9.Pfizer Inc
- 13.9.1.Company details
- 13.9.2.Financial outlook
- 13.9.3.Product summary
- 13.9.4.Recent developments
13.10.Sanofi SA
- 13.10.1.Company details
- 13.10.2.Financial outlook
- 13.10.3.Product summary
- 13.10.4.Recent developments
13.11.Others